Skip to search formSkip to main contentSkip to account menu

exatecan mesylate

Known as: (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo(de)pyrano(3',4'-6,7)indolizino(1,2-b)quinoline-10,13(9H,15H)dione methanesulfonate, Exatecan Mesylate Hydrate 
A semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

DX 8951f

Broader (1)

exatecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane…
Background: DX-8951f is a water-soluble camptothecin derivative with greater in vivo and in vitro activity than topotecan or… 
Highly Cited
2004
Highly Cited
2004
A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).
4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity… 
2004
2004
A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum
Background: To evaluate the antitumor activity, toxicities, and pharmacokinetics (PK) of DX-8951f administered as a 30-min… 
2004
2004
A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction.
2069 Background: Exatecan mesylate is a novel camptothecin analog. Neutropenia and thrombocytopenia are its dose limiting… 
2004
2004
A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer.
4126 Background: Exatecan Mesylate (DX-8951f, Daiichi Pharmaceutical Co., Ltd., Japan) was synthesized to impart greater… 
2004
2004
A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer
4126 Background: Exatecan Mesylate (DX-8951f, Daiichi Pharmaceutical Co., Ltd., Japan) was synthesized to impart greater… 
2004
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Highly Cited
2003
Highly Cited
2003
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
We determined the antitumor and antimetastatic efficacy of the camptothecin analogue DX-8951f in an orthotopic metastatic mouse… 
2003
2003
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane…
BackgroundDX-8951f is a water-soluble camptothecin derivative with greater in vivo and in vitro activity than topotecan or… 
2000
2000
Phase II study of Exatecan Mesylate (DX-8951f) in advanced NSCLC
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)